From: The value of lncRNAs as prognostic biomarkers on clinical outcomes in osteosarcoma: a meta-analysis
LncRNA name | No. of patients | No. of studies | HR(95%CI)-model | P value | heterogeneity | |
---|---|---|---|---|---|---|
I2 | P | |||||
BCAR4 | 228 | 2 | 2.36 (1.13, 4.93)-fixed | 0.022 | 0.0% | 0.453 |
CCAT2 | 90 | 2 | 2.18 (0.81, 5.86)-random | 0.123 | 71.2% | 0.062 |
DANCR | 129 | 2 | 1.65 (0.76, 3.60)-random | 0.209 | 57.1% | 0.127 |
FER1L4 | 121 | 2 | 0.44 (0.16, 0.72)-fixed | 0.032 | 0.0% | 0.945 |
FOXD2-AS1 | 75 | 2 | 1.62 (0.60, 4.38)-fixed | 0.344 | 0.0% | 0.948 |
HNF1A-AS1 | 115 | 2 | 2.63 (1.58, 4.39)-fixed | 0.000 | 0.0% | 0.994 |
HOXA11-AS | 112 | 2 | 1.78 (0.59, 3.36)-fixed | 0.307 | 0.0% | 0.573 |
HOXD-AS1 | 89 | 2 | 1.61 (1.04, 2.50)-fixed | 0.033 | 0.0% | 0.852 |
HULC | 111 | 2 | 5.38 (0.62, 46.50)-random | 0.126 | 71.5% | 0.061 |
LSINCT5 | 166 | 2 | 1.59 (1.04, 2.44)-fixed | 0.031 | 0.0% | 0.695 |
MALAT1 | 605 | 8 | 2.15 (1.67, 2.76)-fixed | 0.000 | 0.0% | 0.676 |
MEG3 | 268 | 2 | 0.55 (0.36, 0.84)-fixed | 0.005 | 0.0% | 0.770 |
NEAT1 | 195 | 3 | 1.96 (1.05, 3.68)-fixed | 0.035 | 0.0% | 0.983 |
ODRUL | 140 | 2 | 1.73 (1.12, 2.67)-fixed | 0.013 | 0.0% | 0.793 |
OIP5-AS1 | 128 | 2 | 1.93 (1.00, 3.73)-fixed | 0.049 | 0.0% | 0.367 |
PCAT1 | 92 | 2 | 2.43 (1.95, 6.24)-random | 0.065 | 87.9% | 0.004 |
PVT1 | 99 | 2 | 1.69 (0.70, 4.06)-fixed | 0.241 | 0.0% | 0.974 |
SNHG12 | 95 | 2 | 1.85 (0.75, 4.58)-fixed | 0.181 | 0.0% | 0.733 |
SNHG16 | 161 | 2 | 1.91 (0.94, 3.86)-fixed | 0.074 | 0.0% | 0.498 |
SNHG20 | 172 | 2 | 1.95 (1.23, 3.09)-fixed | 0.004 | 0.0% | 0.940 |
TP73 | 178 | 2 | 1.90 (1.20, 3.02)-fixed | 0.006 | 0.0% | 0.943 |
TUG1 | 294 | 5 | 1.64 (1.42, 1.92)-fixed | 0.000 | 0.0% | 0.435 |
UCA1 | 286 | 2 | 2.41 (1.42, 4.07)-fixed | 0.001 | 0.0% | 0.809 |
XIST | 299 | 4 | 1.79 (1.40, 2.30)-fixed | 0.000 | 0.0% | 0.601 |
ZFAS1 | 103 | 2 | 1.47 (0.66, 3.23)-fixed | 0.343 | 0.0% | 0.723 |